Ocular Therapeutix, Inc. (OCUL) vs Recursion Pharmaceuticals, Inc. (RXRX)

Ocular Therapeutix, Inc. and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. Ocular Therapeutix, Inc. and Recursion Pharmaceuticals, Inc. are of similar size ($2.2B and $2.1B). Ocular Therapeutix, Inc. grew revenue faster over the last twelve months: −8.14% against −15.1%. Ocular Therapeutix, Inc. has the higher net margin (−579.1% vs −945.9%) and the higher return on invested capital (0.00% vs −92.2%). Across the 18 metrics below, Ocular Therapeutix, Inc. leads on 9 and Recursion Pharmaceuticals, Inc. on 9.

Valuation

Metric OCUL RXRX Biotechnology median
P/E n/m n/m 7.88
P/S 41.70 36.30 11.47
P/B 4.17 2.18 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 31.60 26.34 10.73
Earnings yield (14.72%) (27.81%) (28.84%)
Free cash flow yield (11.75%) (17.79%) (23.03%)

Profitability

Metric OCUL RXRX Biotechnology median
Gross margin 87.11% 3.48% 65.16%
Operating margin (603.04%) (991.72%) 0.00%
Net margin (579.10%) (945.92%) 0.00%
Free cash flow margin (490.07%) (645.82%) 0.00%
Return on equity (72.99%) (56.58%) (57.72%)
Return on assets (53.70%) (41.26%) (49.22%)
Return on invested capital 0.00% (92.22%) 0.00%

Growth

Metric OCUL RXRX Biotechnology median
Revenue growth (TTM) (8.14%) (15.08%) 5.64%
EPS growth (last fiscal year) (16.39%) 14.79% —
Revenue growth, 5-year CAGR 24.45% 48.97% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric OCUL RXRX Biotechnology median
Debt to equity 0.14 0.01 0.00
Current ratio 13.11 5.03 4.73
Net debt to EBITDA 2.51 1.31 0.96

Dividend

Metric OCUL RXRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric OCUL RXRX Biotechnology median
Market cap 2.16b 2.11b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack